markov state transition patient-level microsimulation model Search Results


markov state transition patient-level microsimulation model  (treeage software)
90
treeage software markov state transition patient-level microsimulation model
Markov State Transition Patient Level Microsimulation Model, supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/markov state transition patient-level microsimulation model/product/treeage software
Average 90 stars, based on 1 article reviews
markov state transition patient-level microsimulation model - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
canagliflozin 1d  (Janssen)
90
Janssen canagliflozin 1d
Model parameters
Canagliflozin 1d, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/canagliflozin 1d/product/Janssen
Average 90 stars, based on 1 article reviews
canagliflozin 1d - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
treeage pro 2015  (treeage software)
90
treeage software treeage pro 2015
Model parameters
Treeage Pro 2015, supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/treeage pro 2015/product/treeage software
Average 90 stars, based on 1 article reviews
treeage pro 2015 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Model parameters

Journal: Pharmacoeconomics

Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus

doi: 10.1007/s40273-023-01268-5

Figure Lengend Snippet: Model parameters

Article Snippet: Neslusan, 2018 [ ] , USA , Canagliflozin 300 mg 1d vs. dapagliflozin 10 mg 1d , Janssen Scientific Affairs , Third-party payer , 30 , Markov with microsimulation at the patient level , ECHO-T2DM , None stated , Dual therapy , MET.

Techniques: Comparison, Injection, Filtration, Infection, Cell Counting, Clinical Proteomics

Cost-effectiveness and uncertainty results

Journal: Pharmacoeconomics

Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus

doi: 10.1007/s40273-023-01268-5

Figure Lengend Snippet: Cost-effectiveness and uncertainty results

Article Snippet: Neslusan, 2018 [ ] , USA , Canagliflozin 300 mg 1d vs. dapagliflozin 10 mg 1d , Janssen Scientific Affairs , Third-party payer , 30 , Markov with microsimulation at the patient level , ECHO-T2DM , None stated , Dual therapy , MET.

Techniques: Comparison, Control

General characteristics of the studies

Journal: Pharmacoeconomics

Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus

doi: 10.1007/s40273-023-01268-5

Figure Lengend Snippet: General characteristics of the studies

Article Snippet: Neslusan, 2018 [ ] , USA , Canagliflozin 300 mg 1d vs. dapagliflozin 10 mg 1d , Janssen Scientific Affairs , Third-party payer , 30 , Markov with microsimulation at the patient level , ECHO-T2DM , None stated , Dual therapy , MET.

Techniques: Comparison